Understanding how lung cancer cells show themselves to the immune system
Interrogating the relationship between translational dynamics and non-canonical antigen presentation in lung cancer
This research explores new ways lung cancer cells signal to the body's immune cells, aiming to improve future cancer treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-11135376 on NIH RePORTER |
What this research studies
Our immune system's CD8+ T cells are crucial for fighting cancer by recognizing specific markers, called antigens, on cancer cells. Current immunotherapies often target 'neoantigens,' which are unique to a patient's tumor, but these can vary greatly and limit treatment options. This project looks for other important cancer markers, including those from hidden genetic instructions, to help the immune system better identify and attack lung cancer cells. By finding these new markers, we hope to develop more effective and widely applicable immunotherapies.
Who could benefit from this research
Good fit: This foundational research is relevant to patients with lung cancer, particularly those whose tumors may not respond well to existing immunotherapies that target common neoantigens.
Not a fit: Patients will not receive direct treatment or benefit from this basic research, as it focuses on understanding disease mechanisms rather than immediate clinical application.
Why it matters
Potential benefit: If successful, this work could lead to the development of new and more effective immunotherapies for lung cancer, especially for patients who may not benefit from current treatments.
How similar studies have performed: While current immunotherapies targeting neoantigens have shown success, this approach explores novel, less understood sources of cancer antigens, representing a new direction.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Jaeger, Alex — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Jaeger, Alex
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.